YOLFTbeta
30

Guangzhou Improve Med Instrument

300030 · SHE · Healthcare / Medical Instruments & Supplies

6.90CNY-0.59 (-7.88%)

Price History

Full chart

Market Stats

Previous Close7.49
Open7.35
Day Range6.86 – 7.45
52-Week Range5.61 – 9.00
Volume39.32M
Market Cap2.14B
P/E (TTM)69.20
Forward P/E40.00
EPS0.10
Dividend Yield0.00%
Beta0.46
50-Day Avg6.68
200-Day Avg7.37

About

Improve Medical Instruments Co., Ltd. engages in the provision of relevant technologies, products, and services for clinical laboratory and clinical nursing in China and internationally. It provides clinical laboratory products comprising feces and thrombosis viscoelastic analysis systems; and automatic biosafety decappers; and Q-VELOX, an intelligent molecular diagnostic workstation. The company also offers offers specimen processing equipment, including evacuated blood collection systems, evacuated blood collection tubes, multi-sample needles, blood collection sets, tourniquets and disposable tourniquets, urine collection systems, and holders under IMPROVACUTER brand name; and IMPROMINI capillary blood collection systems, IMPROSWAB microbiological transportation systems, IMPRONURSE infusion pumps and syringe pumps, LONGX urine analysis systems, in-vitro diagnostic reagents, IMPROSAFE safety blood collection needles, IMPROVE sharps containers, liquid biopsy pre-analytical systems, etc. In addition, it provides clinical nursing products, including automatic, handheld, pulsewave, and smart wireless blood pressure monitors; and intelligent management solutions, such as blood collection tube preparation systems, friendly graphic user interfaces, intelligent sorters, multi-function blood collection tables, intelligent queue systems, urine collection tube preparation systems, automatic tube packer systems, and consumable labels, as well as CryoMax vials and liquid nitrogen freezing storage boxes. The company was formerly known as Guangzhou Improve Medical Instruments Co., Ltd. and changed its name to Improve Medical Instruments Co., Ltd. in December 2021. The company was founded in 1996 and is headquartered in Guangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEODr. Hong Yu Yan
  • Employees632
  • HeadquartersNo. 102, Kaiyuan Avenue, Guangzhou, China, 510530, China
  • Websitehttps://www.improve-medical.com

Leadership

  • Dr. Hong Yu YanCFO & Deputy GM · b. 1964
  • Mr. Guangcheng JiangDeputy GM & Non-Independent Director · b. 1968
  • Mr. Wei YuBoard Secretary & Non Independent Director · b. 1986
  • Mr. Ke TianDeputy General Manager · b. 1975
  • Mr. Zhou WeiDeputy General Manager · b. 1979
  • Ning LiChief Accounting Officer
  • Chuan Rong QianVice President

Financials

Income Statement

Currency: CNY2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue44.12M72.32M103.45M140.79M165.87M249.64M304.08M396.74M461.79M545.35M517.10M549.65M549.96M575.06M919.23M799.83M710.77M644.62M581.33M486.26M
Growth (%)-+63.91%+43.04%+36.10%+17.81%+50.51%+21.81%+30.47%+16.40%+18.09%-5.18%+6.29%+0.06%+4.56%+59.85%-12.99%-11.14%-9.31%-9.82%-16.35%
Cost of Revenue18.87M36.42M55.36M74.98M91.92M139.42M171.65M230.20M261.80M308.75M276.72M304.30M335.40M318.97M498.86M490.54M474.56M414.50M368.51M277.14M
Gross Profit25.25M35.90M48.08M65.82M73.95M110.22M132.43M166.53M199.99M236.60M240.38M245.35M214.56M256.09M420.37M309.29M236.21M230.12M212.81M209.12M
Gross Margin57.23%49.65%46.48%46.75%44.58%44.15%43.55%41.98%43.31%43.39%46.49%44.64%39.01%44.53%45.73%38.67%33.23%35.70%36.61%43.01%
Operating Expense15.36M20.64M28.35M37.03M46.32M70.17M102.89M121.78M146.48M198.36M215.60M228.41M358.88M218.51M254.38M279.41M449.05M270.93M329.74M167.27M
Operating Income9.90M15.27M19.74M28.79M27.62M40.06M29.54M44.75M53.51M38.24M24.78M16.93M-144.32M37.58M165.99M29.88M-212.84M-40.81M-116.93M41.85M
Operating Margin22.43%21.11%19.08%20.45%16.65%16.05%9.71%11.28%11.59%7.01%4.79%3.08%-26.24%6.53%18.06%3.74%-29.95%-6.33%-20.11%8.61%
EBITDA11.70M16.88M28.20M36.65M43.76M56.45M65.12M82.41M92.77M96.03M96.42M81.58M-79.59M102.62M227.81M90.29M-154.76M8.93M-73.90M61.82M
EBITDA Margin26.52%23.34%27.26%26.03%26.38%22.61%21.42%20.77%20.09%17.61%18.65%14.84%-14.47%17.84%24.78%11.29%-21.77%1.39%-12.71%12.71%
Net Income8.34M13.19M20.46M26.91M29.02M35.67M37.47M46.12M53.06M39.84M30.48M11.16M-136.80M26.02M162.52M18.57M-198.30M-63.20M-117.90M14.53M
Net Income Margin18.91%18.24%19.78%19.11%17.50%14.29%12.32%11.62%11.49%7.30%5.89%2.03%-24.87%4.53%17.68%2.32%-27.90%-9.80%-20.28%2.99%
R&D-4.60M4.45M--13.71M18.93M19.03M24.90M27.22M26.32M19.42M25.52M23.51M46.56M42.33M43.67M37.52M31.90M23.65M
R&D as % of Total Revenue-6.36%4.30%--5.49%6.22%4.80%5.39%4.99%5.09%3.53%4.64%4.09%5.07%5.29%6.14%5.82%5.49%4.86%
Interest Expense5.69K16.17K725.15K743.56K162.94K173.58K25.33K338.08K1.66M13.07M16.79M26.85M26.72M29.98M25.24M25.80M20.28M16.56M11.58M5.14M
Interest Expense % of Total Revenue0.01%0.02%0.70%0.53%0.10%0.07%0.01%0.09%0.36%2.40%3.25%4.88%4.86%5.21%2.75%3.23%2.85%2.57%1.99%1.06%

Balance Sheet

Currency: CNY2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets39.95M73.88M141.69M657.84M651.24M716.72M766.53M883.08M1.02B1.44B1.47B1.75B1.51B1.51B1.74B1.83B1.56B1.43B1.24B1.03B
Total Liabilities20.62M15.61M62.96M94.31M58.69M68.47M78.60M110.38M237.33M508.88M515.70M782.15M695.67M668.54M741.94M794.63M737.57M663.63M600.28M371.82M
Total Equity19.33M58.27M78.73M563.53M592.55M620.83M646.03M684.35M729.97M920.68M944.38M954.89M810.84M835.98M999.73M1.00B784.35M723.08M606.73M620.34M
Cash3.59M13.28M28.28M469.63M387.33M331.14M290.40M299.65M138.62M167.84M128.27M271.40M234.09M197.14M217.56M345.74M221.05M214.71M247.95M160.32M
Total Debt--30.00M39.50M----130.17M310.14M346.54M599.82M499.80M470.90M442.50M524.83M426.29M365.28M336.05M-
Net Debt-3.59M-13.28M1.72M-430.13M-387.33M-331.14M-290.40M-299.65M-8.45M142.30M218.28M328.42M265.71M273.76M224.95M179.09M205.25M150.57M88.10M-

Cash Flow

Currency: CNY2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow6.57M2.65M24.76M33.03M28.86M38.86M36.06M44.38M-108.20M-8.02M23.19M142.19M56.04M49.16M141.27M171.74M42.48M79.90M81.84M109.90M
Investing Cash Flow-2.53M-9.91M-33.89M-64.57M-70.86M-88.67M-64.35M-72.11M-204.13M-202.10M-32.65M-104.89M-37.01M-99.91M-61.30M-39.81M-44.64M-38.50M13.50M-
Financing Cash Flow-1.31M16.95M24.21M472.94M-39.94M-7.46M-10.67M33.23M141.06M246.18M-30.16M108.91M-52.80M11.37M-58.32M-2.57M-120.83M-50.09M-60.63M-
Capital Expenditure2.53M9.97M33.91M64.57M70.86M88.04M53.46M62.21M82.33M95.32M26.39M96.01M50.39M54.44M56.82M71.05M58.04M43.70M51.28M24.12M
Free Cash Flow4.04M-7.32M-9.14M-31.54M-42.01M-49.18M-17.40M-17.83M-190.53M-103.34M-3.21M46.18M5.64M-5.28M84.46M100.69M-15.56M36.20M30.55M85.77M
Dividends Paid--673.02K740.41K346.74K7.46M8.91M8.88M8.96M19.01M22.74M13.40M30.65M26.14M26.79M9.88M12.37M15.94M11.97M5.50M
FCF to OCF61.48%-276.12%-36.92%-95.47%-145.58%-126.54%-48.25%-40.17%176.09%1288.63%-13.83%32.48%10.07%-10.73%59.78%58.63%-36.64%45.31%37.34%78.05%
Dividend Paid to FCF---7.36%-2.35%-0.83%-15.16%-51.18%-49.81%-4.71%-18.40%-709.17%29.02%543.27%-495.44%31.72%9.81%-79.46%44.02%39.16%6.41%

Earnings

Report DateMar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Feb 26, 2014May 28, 2014Sep 3, 2014Oct 17, 2014Feb 15, 2015Apr 27, 2015Aug 3, 2015Oct 23, 2015Jan 29, 2016Apr 25, 2016Aug 25, 2016Oct 28, 2016Feb 28, 2017Apr 26, 2017Aug 25, 2017Oct 29, 2017Feb 28, 2018Apr 26, 2018Aug 27, 2018Oct 24, 2018Apr 25, 2019Aug 14, 2019Oct 26, 2019Mar 7, 2020Apr 25, 2020Aug 15, 2020Oct 30, 2020Apr 21, 2021Aug 7, 2021Oct 28, 2021Apr 25, 2022Aug 26, 2022Oct 26, 2022Apr 27, 2023Aug 30, 2023Oct 27, 2023May 21, 2024Aug 15, 2024Oct 26, 2024May 21, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------------------------------
EPS Actual0.010.020.030.040.020.030.030.040.030.030.030.030.010.030.060.060.020.040.070.040.030.030.040.040.020.020.020.030.020.020.01-0.010.010.030.01-0.490.040.020.010.040.310.33-0.150.18-0.18-0.120.01-0.070.04-0.01-0.02-0.21-0.01-0.120.030.020.03-0.030.070.03
Surprise------------------------------------------------------------
Timing------------------Pre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-Pre-marketAfter-hoursPre-marketPre-market---------------After-hours--After-hours-----

Key Statistics & Ratios

Market Cap2.14B
Enterprise Value2.06B
Trailing P/E69.20
Forward P/E40.00
PEG Ratio0.00
Price / Sales4.55
Price / Book3.23
EPS0.10
Book Value2.11
Revenue (TTM)470.40M
Gross Profit (TTM)204.23M
EBITDA99.14M
Profit Margin6.39%
Operating Margin15.60%
Return on Equity4.66%
Return on Assets4.05%
Shares Outstanding309.19M
Shares Float208.87M
Beta0.46
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20221×
0.04Jul 6, 2022
20211×
0.03Jun 11, 2021
20181×
0.03Jun 20, 2018
20161×
0.03Jul 26, 2016
20151×
0.03May 26, 2015
20141×
0.03Apr 25, 2014
20131×
0.03May 31, 2013
20121×
0.03May 25, 2012
20111×
0.03May 13, 2011

Stock Splits

  • Apr 25, 201420:10
  • May 13, 201120:10